For US Healthcare Professionals
I am a:
ACR20=20% improvement in American College of Rheumatology composite measures of arthritis; ANCOVA=analysis of covariance; CMH=Cochran-Mantel-Haenszel; IGA=Investigator's Global Assessment; IGA 0/1=proportion of patients who achieved an IGA score of cleared (0) or minimal (1) using a 5-point scale where psoriatic lesions are graded by the investigator for induration, erythema, and scaling on a scale of 0 to 4: cleared, except for discoloration (0), minimal (1), mild (2), moderate (3), or severe (4); LS=least squares; mFAS=modified full analysis set; mvdH-S=modified van der Heijde-Sharp; ND/MD=natural disaster/major disruption; NRI=nonresponder imputation; NS=not significant; PASI 90=proportion of patients who achieved 90% or more reduction (or improvement) in Psoriasis Area and Severity Index (PASI) score from baseline.
‡The primary endpoint P value is multiplicity controlled using a fixed sequence testing procedure and can be used to determine statistical significance. Statistics are based on the CMH test across multiply imputed datasets.
§Efficacy analyses are from the mFAS, which included all randomized patients, excluding those from Ukraine sites rendered unable to support key study operations due to major disruptions.
||Statistics are based on ANCOVA. Missing data and data impacted by ND/MD were imputed using multiple imputation.
¶Major secondary endpoint P value is multiplicity controlled using a fixed sequence testing procedure and can be used to determine statistical significance. Statistics are based on ANCOVA across multiply imputed datasets.
Go beyond the skin.* Proven to preserve the joint.†
*TREMFYA® was approved in 2017 for use in adult patients with moderate to severe plaque psoriasis, and was approved in 2020 for use in adult
patients with active psoriatic arthritis.
Proven skin clearance in PsO and joint preservation in PsA
At Week 16 in adult patients with moderate to severe plaque PsO:
VOYAGE co-primary endpoints (NRI): VOYAGE 1—PASI 90: TREMFYA® 73% (241/329) vs placebo 3% (5/174) (P<0.001); IGA 0/1: TREMFYA® 85% (280/329) vs placebo 7% (12/174) (P<0.001); VOYAGE 2—PASI 90: TREMFYA® 70% (347/496) vs placebo 2% (6/248) (P<0.001); IGA 0/1: TREMFYA® 84% (417/496) vs placebo 8% (21/248) (P<0.001).1-3
†At Week 24 in adult patients with active PsA:
Major secondary endpoint in a phase 3b study (APEX): TREMFYA® showed a greater reduction in structural damage progression (LS mean change from baseline in total mvdH-S score) vs placebo (0.54 vs 1.35; P<0.001).5-7‡§||
See structural damage data
Safety demonstrated across PsO and PsA
TREMFYA® has a proven safety profile across psoriatic disease with 5 years of data in adult patients with moderate to severe plaque PsO and 2 years¶ of data in adult patients with active PsA.8,9
If clinically indicated, evaluate liver enzymes and bilirubin at baseline, and periodically thereafter according to routine patient management.1
See safety profile
Only# fully human, dual-acting** IL-23i to target the source of inflammation
Selective IL-23 inhibitors like TREMFYA® block IL-23 and regulate IL-17A/F and IL-22 cytokines.1††
TREMFYA® is the only# selective, dual-acting†† IL-23 inhibitor designed also to neutralize inflammation at its cellular source by binding to CD64.10††‡‡
#"Only" based on approved IL-23 inhibitors for active PsA as of February 2026.
**Dual-acting is defined as blocking IL-23 and binding to CD64.
††The clinical significance is unknown.
‡‡Findings are limited to in vitro studies.
See MOA details
Outstanding§§ access
TREMFYA® has nearly‖‖ 100% commercial and over 90% Medicare Part D coverage.
Source: Managed Markets Insight & Technology, LLCTM, a trademark of MMIT, as of September 2025. Collected as of 09/25 and may change. These percentages may not represent 100% of formulary lives due to data limitations.
See access
Data on File, as of 09/25. Collected as of 09/25 and may change.
CD64=cluster of differentiation 64; IL-17A/F=interleukin 17A/F; IL-22=interleukin 22; IL-23=interleukin 23; IL-23i=interleukin-23 inhibitor; MACE=major adverse cardiovascular event (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke); MOA=mechanism of action.
‡Efficacy analyses are from the mFAS, which included all randomized patients, excluding those from Ukraine sites rendered unable to support key study operations due to major disruptions.
§Statistics are based on ANCOVA. Missing data and data impacted by ND/MD were imputed using multiple imputation.
||Major secondary endpoint P value is multiplicity controlled using a fixed sequence testing procedure and can be used to determine statistical significance. Statistics are based on ANCOVA across multiply imputed datasets.
¶2 years represents Week 112.
§§”Outstanding” means >90% number of covered lives.
‖‖“Nearly” means absolute difference less than +/- 2% of the actual number. Within 2% of the access being stated.
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417. 3. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431. 4. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 5. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Oral presentation at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. 6. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Abstract presented at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. Late-Breaking Abstracts Session II. 7. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study. Ann Rheum Dis. 2025;84(12):1983-1994. 8. Data on file. Janssen Biotech, Inc. 9. McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475-485. 10. Krueger J, Eyerich K, Greving C, et al. Differentiation of therapeutic antibodies targeting IL-23. Poster presented at: 2022 Society for Investigative Dermatology; May 18-21, 2022; Portland, OR.
IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PsO
